Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 622-628

  Thomassen, Irene ^a,b   Van Gestel, Yvette R ^b   Van Ramshorst, Bert ^c   Luyer, Misha D ^a   Bosscha, Koop ^d   Nienhuijs, Simon W ^a   Lemmens, Valery E ^b,e   De Hingh, Ignace H ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b Erasmus University Rotterdam and Eindhoven Cancer Registry   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

gastric cancer; incidence; metastasis; peritoneal carcinomatosis; prognosis; treatment

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVARY METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIGNET RING CARCINOMA; SURVIVAL RATE;

EID: 84888009393     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28373     Document Type: Article

References (32)

1. Crew KD, Neugut AI,. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-62.
2. Sugarbaker PH, Yonemura Y,. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000; 58: 96-107.
3. Gretschel S, Siegel R, Estevez-Schwarz L, et al. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 2006; 93: 1530-5.
4. Bonenkamp JJ, Sasako M, Hermans J, et al. Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001; 48: 1219-21.
5. Hioki M, Gotohda N, Konishi M, et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010; 34: 555-62.
6. Abbasi SY, Taani HE, Saad A, et al. Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes. Gastrointest Cancer Res 2010; 4: 122-7.
7. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010: CD004064.
8. Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011; 104: 692-8.
9. Rossi CR, Pilati P, Mocellin S, et al. Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma. Suppl Tumori 2003; 2: S54-7.
10. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139: 20-6.
11. Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119: 437-44.
12. Schouten LJ, Hoppener P, van den Brandt PA, et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369-76.
13. Zu H, Wang F, Ma Y, Xue Y,. Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One 2013; 8: e54502.
14. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2010; 128: 2717-25.
15. Ceelen WP, Bracke ME,. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009; 10: 72-9.
16. Knorr C, Reingruber B, Meyer T, et al. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis 2004; 19: 181-7.
17. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-63.
18. Sugarbaker PH,. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994; 37: S115-S22.
19. Honore C, Goere D, Messager M, et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: Results of a multicentre retrospective study. Eur J Surg Oncol 2013; 39: 235-41.
20. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C,. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011; 254: 684-93; discussion 693.
21. Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009; 250: 878-87.
22. Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011; 2: 77-84.
23. Thomassen I, Lemmens VE, Nienhuijs SW, et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study. Pancreas 2013; 42: 72-5.
24. Klaver YL, Lemmens VE, Creemers GJ, et al. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011; 22: 2250-6.
25. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-32.
26. Liu X, Cai H, Sheng W, et al. Long-term results and prognostic factors of gastric cancer patients with microscopic peritoneal carcinomatosis. PLoS One 2012; 7: e37284.
27. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-32.
28. Dovern E, de Hingh IH, Verwaal VJ, et al. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. Eur J Gynaecol Oncol 2010; 31: 256-61.
29. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449-56.
30. Glehen OYY, Sugarbaker PH,. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Ciné Med 2013.
31. Costa WL, Jr, Coimbra FJ, Ribeiro HS, et al. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol 2012; 10: 195.
32. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14: 2702-13.